Brents, Leslie A.

Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007) · Cancer Cell

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 983

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 637

Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma

Chesi, M., Bergsagel, P. L., Shonukan, O. O., Martelli, M. L., Brents, L. A., Chen, T., Schröck, E., Ried, T., & Kuehl, W. M. (1998) · Blood

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 400

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

Bergsagel, P. L., Chesi, M., Nardini, E., Brents, L. A., Kirby, S. L., & Kuehl, W. M. (1996) · Proceedings of the National Academy of Sciences

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 367

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., & Bergsagel, P. L. (2001) · Blood

Multiple Myeloma Research and TreatmentsFibroblast Growth Factor Research

Cited by 289